AARONS, L. see MITHWANI, S.
AARONS, L. see PITSIU, M.
AHERNE, Z. see BLAKEY, G.E.
AKHONDZADEH, S., MOHAMMADI, M.R., ERFANI, S., TEHRANIDOOST, M., AMINI, H. & KASHANI, L. A clinical trial of adjunctive cyproheptadine in the treatment of autistic disorder: a double-blind and placebo controlled trial: 670
AKHONDZADEH, S., MOHAMMADI, M.R., MAHAGERI, H., AMINI, H. & KASHANI, L. Ritanserin as an adjunct to lithium and haloperidol for the treatment of patients with acute mania: a double-blind and placebo controlled trial: 674
AKICI, A., KALAÇA, S., UGURLU, M.Ü., KARAALP, A., ÇALI, Ş. & OKTAY, Ş. Impact of a short postgraduate course in rational pharmacotherapy for general practitioners: 310
AKIZAWA, T. see OHASHI, N.
AKTAN, Y. seeÖZDEMIR, M.
ALBRECHT, S. see IHMSEN, H.
ALLEGAERT, K., VERBESSELT, R., DEVLIEGER, H., DE HOON, J. & TIBBOEL, D. Cerebrospinal fluid pharmacokinetics of paracetamol after intravenous propacetamol in a preterm infant: 224
ALLEGRE, T. see SOLAS, C.
ALLEN, K.M. see DOOLEY, M.J.
AMINI, H. see AKHONDZADEH, S.
AMMIT, A.J. see JIANG, X.
ANDOH, N. see MINAMI, J.
ANTILA, S., KIVIKKO, M., LEHTONEN, L., EHA, J., HEIKKILÄ, A., POHJANJOUSI, P. & PENTIKÄINEN, P.J. Pharmacokinetics of levosimendan and its circulating metabolites in patients with heart failure after an extended continuous infusion of levosimendan: 412
ARAKI, N. see TSURUOKA, S.
ARONSON, J.K. see GRAHAME-SMITH, D.G.
ARONSON, J.K. see LOKE, Y.K.
ARONSON, J.K. Drug interactions – information, education, and the British National Formulary: 371
ARONSON, J.K. In defence of polypharmacy: 119
ARONSON J.K. On Being 30: 1
ARONSON, J.K. On the waterfront – the breadth and depth of clinical pharmacology: 693
ARONSON, J.K. Rational prescribing, appropriate prescribing: 229
ARSHAD, S. see NORRIS, V.
ATTHOBARI, J., MONSTER, T.B.M., DE JONG, P.E., DE JONG-VAN DEN BERG FOR THE PREVEND STUDY GROUP, L.T.W. The effect of hypertension and hypercholesterolemia screening with subsequent intervention letter on the use of blood pressure and lipid lowering drugs: 328
ATTINÀ, T., OLIVER, J.J. & WEBB, D.J. Investigation of the effects of inhaled tiotropium on the response to acetylcholine in the forearm vasculature: 681
AYNACIOGLU, A.S., NACAK, M., FILIZ, A., EKINCI, E. & ROOTS, I. Protective role of glutathione S-transferase P1 (GSTP1) Val105Val genotype in patients with bronchial asthma: 213
BÅÅTHE, S. see JOHNSTON, D.
BAAS, P. see DE JONGE, M.E.
BACK, D.J. see HARTKOORN, R.C.
BACKMAN, J.T. see GRANFORS, M.T.
BACKMAN, J.T.see KYRKLUND, C.
BACKMAN, J.T. see NIEMI, M.
BARILLA, D. see KOVARIK, J.M.
BARTELINK, I.H., BRÜGGEMANN, R.J.M., VAN ASSELT, G.J., OVERDIEK, J.W.P.M., BOERMANS, P.A.M.M. & OOSTVOGEL, P.M. Improving the quality of antibiotic treatment in a Dutch hospital: 355
BATEMAN, D.N. see STRACHAN, E.M.
BATES, C.E.see LEE, D.K.C.
BATTY, G.M. see JACKSON, S.H.D.
BATTY, K.T., ILETT, K.F. & DAVIS, T.M.E. Protein binding and α : β anomer ratio of dihydroartemisinin in vivo: 529
BÉGAUD, B. see MARTIN, K.
BECK, C.R., YEO, W.W. & ROWLAND YEO, K. Cost-effectiveness of smoking cessation therapy compared with statins to prevent cardiovascular events: 689
BEIJNEN, J.H. see CROMMENTUYN, K.M.L.
BEIJNEN, J.H. see DE JONGE, M.E.
BEIJNEN, J.H. see KUPPENS, I.E.L.M.
BELLMANN, R., KUCHLING, G., DEHGHANYAR, P., ZEITLINGER, M., MINAR, E., MAYER, B.X., MÜLLER, M. & JOUKHADAR, C. Tissue pharmacokinetics of levofloxacin in human soft tissue infections: 563
BELTMAN, F.W. see GREVING, J.P.
BENNETT, K. see FITZ-SIMON, N.
BENNETT, K. see ODUBANJO, E.
BENNETT, K. see TEELING, M.
BENNETT, K. see USHER, C.
BENNETT, K. see WILLIAMS, D.
BENNETT, K., O’CONNOR, H., THORNTON, O., DOBSON, M., BUCKLEY, M.J., O’MORAIN, C., QUASIM, A. & FEELY, J. Underuse of eradication therapy following Helicobacter pylori testing: 666
BENNETT, P.N. & BROWN, M.J. Clinical Pharmacology: 223
BERRY, N.S. see PERSKY, A.M.
BEUDEKER, Q.H. see OLIVER, J.J.
BJARNASON, I.T., CHARLETT, A., DOBBS, R.J., DOBBS, S.M., OWEN, R.J., OXLADE, N., PRICE, A.B. & WELLER, C. Response of gait in idiopathic parkinsonism to Helicobacter pylori eradication: 689
BLACK, J. see BOYCE, M.
BLAIR, E.Y.L. see SLAVIERO, K.A.
BLAIR, E.Y.L., RIVORY, L.P., CLARKE, S.J. & MCLACHLAN, A.J. Population pharmacokinetics of raltitrexed in patients with advanced solid tumours: 416
BLAKEY, G.E., LOCKTON, J.A., PERRETT, J., NORWOOD, P., RUSSELL, M., AHERNE, Z. & PLUME, J. Pharmacokinetic and pharmacodynamic assessment of a five-probe metabolic cocktail for CYPs 1A2, 3A4, 2C9, 2D6 and 2E1: 162
BOCHNER, F. see FOSTER, D.J.R.
BODENSTEIN, J. see BRINK, C.B.
BOERMANS, P.A.M.M. see BARTELINK, I.H.
BOLK, J.H. see FRANSON, K.L.
BONAR, H.L. see DISHY, V.
BOSCH, D.A. see MERKUS, P.
BOSCH, T.M. see KUPPENS, I.E.L.M.
BOUW, R. see EDEROTH, P.
BOWLER, A. see OLIVER, J.J.
BOYCE, M. see CALDER, N.
BOYCE, M. see NORRIS, V.
BOYCE, M., WARRINGTON, S., NENTWICH, H., NORRIS, V., HULL, R. & BLACK, J., Effect of repeated doses of Yf476, a gastrin antagonist, on pentagastrin-induced changes in volume, H+ content and pH of gastric aspirate in healthy subject: 684
BOYD, K.M. see CARLSON, R.V.
BRATER, D.C. see MACFADYEN, R.J.
BRETT, S.E., RITTER, J.M., TURNER, C. & CHOWIENCZYK, P.J. An acute elevation of homocysteine by methionine loading increases exercise but not resting blood pressure: 672
BRIEN, J.E. see EASTON, K.L.
BRIGHT, J. see DOOLEY, M.J.
BRINK, C.B., HARVEY, B.H., BODENSTEIN, J., VENTER, D.P. & OLIVER, D.W. Recent advances in drug action and therapeutics: Relevance of novel concepts in G-protein-coupled receptor and signal transduction pharmacology: 373
BROUWER, K.L.R. see PERSKY, A.M.
BROUWERS, J.R.B.J. see DENEER, V.H.M.
BROUWERS, J.R.B.J. see VAN ROON, E.N.
BROUWERS, J.R.B.J. see WILTING, I.
BROWN, H.S. see ITO, K.
BROWN, M.J. see BENNETT, P.N.
BRÜGGEMANN, R.J.M. see BARTELINK, I.H.
BRUYN, G.A.W. see VAN ROON, E.N.
BRYANT, C.A. see FORD, G.A.
BÜHRMANN, S. see WENZEL, R.R.
BUCKLEY, M.J. see BENNETT, K.
BURGGRAAF, J. see KAMERLING, I.M.C.
BURHENNE, J. see FRÖHLICH, M.
ÇALI, Ş. see AKICI, A.
CALDER, N., BOYCE, M., POSNER, J. & SCIBERRAS, D. Clinical pharmacology studies in UK Phase 1 units: an AHPPI survey 1999–2000: 76
CAMPBELL-O’SULLIVAN, S.P. see GREENHAFF, P.L.
CANTARINI, M.V., WATKINS, C.L., GROWCOTT, J. & HUGHES, A.M. An investigation of components of variance and tachyphylaxis in a placebo-controlled intravenous tyramine study: 657
CAREY, D.L. see DOOLEY, M.J.
CARLSON, R.V., BOYD, K.M. & WEBB, D.J. The revision of the Declaration of Helsinki: past, present and future: 695
CARTWRIGHT, C.S., SAVAGE, C.M. & LENNARD, L. Concordance of thiopurine methyltransferase genotype and phenotype in childhood leukaemia: 685
CATE, T.T. see OLIVER, J.J.
CHAMBERLAIN, P.J. see NAISBITT, D.J.
CHAN, C. see HUA, T.C.
CHANDLER, B. see HARTKOORN, R.C.
CHAPMAN, C.B. see EASTON, K.L.
CHARLESWORTH, B.R. see KÅGEDAL, M.
CHARLETT, A. see BJARNASON, I.T.
CHEMLA, C. see TRENQUE, T.
CHESTER, N., MOTTRAM, D.R., REILLY, T. & POWELL, M. Elimination of ephedrines in urine following multiple dosing: the consequences for athletes, in relation to doping control: 62
CHEUNG, B.M.Y., LAUDER, I.J., LAU, C.-P. & KUMANA, C.R. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes: 640
CHOONG, L. see NORRIS, V.
CHOWIENCZYK, P.J. see BRETT, S.E.; RAMBARAN, C.
CHUI, J., TORDOFF, J., KENNEDY, J. & REITH, D. Trends in accessibility to medicines for children in New Zealand: 1998–2002: 322
CLARKE, S.J. see BLAIR, E.Y.L.
CLARKE, S.J. see SLAVIERO, K.A.
CLELAND, J.G.F. see MORANT, S.V.
COHEN, A.F. see FRANSON, K.L.
COHEN, A.F. see KAMERLING, I.M.C.
COLLER, J.K. see DAVIES, B.J.L.
COLLER, J.K. see HUTCHINSON, M.R.
COLLER, J.K., KREBSFAENGER, N., KLEIN, K., WOLBOLD, R., NÜSSLER, A., NEUHAUS, P., ZANGER, U.M., EICHELBAUM, M. & MÜRDTER, T.E. Large interindividual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicity: 105
COLLET, J.-P. see QUACH, C.
CONSTANTIN-TEODOSIU, D. see GREENHAFF, P.L.
CORDEN, Z. see NORRIS, V.
CORNET, F. see FRANSON, K.L.
CORTI, R. see WORTHLEY, M.I.
COURTNEY, R., WEXLER, D., RADWANSKI, E., LIM, J. & LAUGHLIN, M. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults: 218
COWAN, C. see PURKINS, L.
CREWE, H.K. seeÖZDEMIR, M.
CROMMENTUYN, K.M.L., HUITEMA, A.D.R., VAN HEESWIJK, R.P.G., MATHÔT, R.A.A., SCHERPBIER, H.J., KUIJPERS, T.W. & BEIJNEN, J.H. Population pharmacokinetics of nelfinavir in hiv-1-infected children: 355
CRUDEN, N.L., WITHEROW, F.N., JOHNSTON, N.R., WEBB, D.J., FOX, K.A.A. & NEWBY, D.E. Bradykinin contributes to the systemic haemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure: 671
CURRIE, G.P. see LEE, D.K.C.
DALE, M.M. see RANG, H.P.
DALY, A.K. see KAMALI, F.
DALY, A.K. & KING B.P. CYP3A5 phenotype-genotype correlations in a British population: 664
DANHOF, M. see SWART, E.L.
DAVEY, P.G. see MORANT, S.V.
DAVIES, B.J.L., COLLER, J.K., JAMES, H.M., GILLIS, D., SOMOGYI, A.A., HOROWITZ, J.D., MORRIS, R.G. & SALLUSTIO, B.C. Clinical inhibition of CYP2D6-catalysed metabolism by the antianginal agent perhexiline: 456
DAVIES, S.J.C., EAYRS, S., PRATT, P. & LENNARD, M.S. Potential for drug interactions involving cytochromes P450 2D6 and 3A4 on general adult psychiatric and functional elderly psychiatric wards: 464
DAVIS, T.M.E. see BATTY, K.T.
DAVIS, T.M.E. see HUNG, T.-Y.
DAVIS, T.M.E. see KARUNAJEEWA, H.
DAY, R.O. see JIANG, X.
DE BOER, A. see MAITLAND-VAN DER ZEE, A.H.
DE BOER, A. see MANTEL-TEEUWISSE, A.K.
DE BOER, A. see REIJNTJENS, S.
DE BOER, A. see SCHELLEMAN, H.
DE BRABANDER, C. see VAN DEN ABEELE, W.M.
DE HOON, J. see ALLEGAERT, K.
DE HOON, J.N.J.M. see VANMOLKOT, F.H.M.
DE JONG, P.E. see ATTHOBARI, J.
DE JONGE, M.E., VAN DEN BONGARD, H.J.G.D., HUITEMA, A.D.R., MATHÔT, R.A.A., ROSING, H., VAN MAANEN, R., KOOPMAN-KROON, C., BAAS, P., VAN ZANDWIJK, N., KEESSEN, M., RODENHUIS, S., BEIJNEN, J.H. & SCHELLENS, J.H.M. Bayesian pharmacokinetically guided dosing of paclitaxel in patients with non-small cell lung cancer: 356
DE JONGH, J. see SWART, E.L.
DE JONG-VAN DEN BERG FOR THE PREVEND STUDY GROUP, L.T.W. see ATTHOBARI, J.
DE KAM, M.L. see KAMERLING, I.M.C.
DE LAET, C.E.D.H. see SCHOOFS, M.W.C.J.
DE LONGUEVILLE, M. see PITSIU, M.
DE NIET, S. see MALONNE, H.
DE SMET, P.A.G.M. see VISSER, L.E.
DE VRIES, R. see YASUI-FURUKORI, N.
DEGENER, J.E. see MOL, P.G.M.
DEGRAEUWE, P.L.J. see REIJNTJENS, S.
DEHGHANYAR, P. see BELLMANN, R.
DENEER, V.H.M., KINGMA, J.H., LIE-A-HUEN, L., PROOST, J.H., VAN HEMEL, N.M., UYTDEHAAG, G.M.M., DUNSELMAN, P.H.J.M., STUURMAN, A. & BROUWERS, J.R.B.J. Cardioversion of atrial fibrillation with a loading dose of flecainide tablets or an oral solution of a mixture of flecainide and cisapride: 356
DENIG, P. see GREVING, J.P.
DENIG, P. see MOL, P.G.M.
DENIG, P., SCHAARS, C.F., KASJE, W.N. & HAAIJER-RUSKAMP, F.M. Patient, doctor, and organisational factors affecting hypertension management in patients with type 2 diabetes: 357
DENIS, M.B. see HUNG, T.-Y.
DENIS, M.B. see KARUNAJEEWA, H.
DENVIR, M.A. see LESLIE, S.J.
DEPLANQUE, D., LEYS, D., PARNETTI, L., SCHMIDT, R., FERRO, J., REUCK, J.D., MAS, J.-L. & GALLAI, V. Stroke prevention and atrial fibrillation: reasons leading to an inappropriate management. Main results of the SAFE II study: 798
DERRY, S. see LOKE, Y.K.
DEVLIEGER, H. see ALLEGAERT, K.
DHIVER, C. see SOLAS, C.
DINGEMANSE, J. & VAN GIERSBERGEN, P.L.M. Influence of mild liver impairment on the pharmacokinetics of tezosentan, a drug excreted unchanged into bile: 344
DISHY, V., HARRIS, P.A., PIERCE, R., PRASAD, H.C., SOFOWORA, G., BONAR, H.L., WOOD, A.J.J. & STEIN, C.M. Sildenafil does not improve nitric oxide-mediated endothelium-dependent vascular responses in smokers: 209
DITTERS, J.M. see VAN RIEMSDIJK, M.M.
DOBBS, N.A. see RALPH, L.D.
DOBBS, R.J. see BJARNASON, I.T.
DOBBS, S.M. see BJARNASON, I.T.
DOBSON, M. see BENNETT, K.
DOECKE, C.J. see DOOLEY, M.J.
DONNELLY, R. Characterizing variability in cardiovascular drug responses: 535
DOOLEY, M.J., ALLEN, K.M., DOECKE, C.J., GALBRAITH, K.J., TAYLOR, G.R., BRIGHT, J. & CAREY, D.L. A prospective multicentre study of pharmacist initiated changes to drug therapy and patient management in acute care government funded hospitals: 513
DROGOUL, M.-P. see SOLAS, C.
DUBOIS, E.A. see FRANSON, K.L.
DUKE, C.C. see JIANG, X.
DUMONT, G.J.H., OOSTERINK, B.J., PALTANSING, S., VAN BURGEL, N., VAN DER LINDEN, M., SCHOEMAKER, R. & VAN GERVEN, J.M.A. Determination of alcohol infusion rate by clamping of breath alcohol concentration – a comparison with modelled infusion regimens based on individual pharmacokinetics: 357
DUNSELMAN, P.H.J.M. see DENEER, V.H.M.
DUPOUY, D. see TRENQUE, T.
DURAND, A. see SOLAS, C.
DUVAUCHELLE, T. see KÅGEDAL, M.
EASTON, K.L., CHAPMAN, C.B. & BRIEN, J.E. Frequency and characteristics of hospital admissions associated with drug-related problems in paediatrics: 611
EAYRS, S. see DAVIES, S.J.C.
EDEROTH, P., TUNBLAD, K., BOUW, R., LUNDBERG, C.J.F., UNGERSTEDT, U., NORDSTRÖM, C.-H. & HAMMARLUND-UDENAES, M. Blood–brain barrier transport of morphine in patients with severe brain trauma: 427
EDWARDS, G. see MITHWANI, S.
EGBERTS, A.C.G. see WILTING, I.
EHA, J. see ANTILA, S.
EICHELBAUM, M. see COLLER, J.K.
EKINCI, E. see AYNACIOGLU, A.S.
EKINS-DAUKES, S. see KRISHNAMOORTHY, N.
EKINS-DAUKES, S. see NOVAK, P.
EKINS-DAUKES, S. see TANAKA, M.
ERFANI, S. see AKHONDZADEH, S.
ERIKSSON U.G. see JOHNSTON, D.
EVE, M.D. see PURKINS, L.
FARDON, T.C. see LEE, D.K.C.
FARRELL, J. see NAISBITT, D.J.
FARRELL, J. see WU, Y.
FARRELL, J., GIBNEY, C.A., PIRMOHAMED, M., PARK, B.K. & NAISBITT, D.J. Characterization of drug-specific CD4+ T-cells expressing the skin homing receptor CCR10 in lamotrigine hypersensitivity: 690
FEELY, J. see BENNETT, K.
FEELY, J. see FITZ-SIMON, N.
FEELY, J. see MAHMUD, A.
FEELY, J. see MCNULTY, M.
FEELY, J. see ODUBANJO, E.
FEELY, J. see TEELING, M.
FEELY, J. see USHER, C.
FEELY, J. see WILLIAMS, D.
FERRO, J. see DEPLANQUE, D.
FILIZ, A. see AYNACIOGLU, A.S.
FITZPATRICK, A. see KUPPENS, I.E.L.M.
FITZ-SIMON, N., BENNETT, K. & FEELY, J. A model for the probability of discontinuation of antihypertensive therapy: 682
FORD, G.A., BRYANT, C.A., MANGONI, A.A. & JACKSON, S.H.D. Stroke, dementia, and drug delivery: 15
FORRESTER, T. see RAMBARAN, C.
FOSTER, D.J.R. see HUTCHINSON, M.R.
FOSTER, D.J.R., SOMOGYI, A.A., WHITE, J.M. & BOCHNER, F. Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients: 742
FOURRIER, A. see MARTIN, K.
FOX, K.A.A. see CRUDEN, N.L.
FRANCES, C., HOIZEY, G., MILLART, H. & TRENQUE, T. Paediatric methylphenidate (Ritalin®) restrictive conditions of prescription in France: 115
FRANSON, K.L., DUBOIS, E.A., VAN GERVEN, J.M.A., CORNET, F., BOLK, J.H. & COHEN, A.F. Teaching resource centre (TRC): teaching clinical pharmacology in an integrated medical school curriculum: 358
FREARSON, R. see KAMALI, F.
FRÖHLICH, M., BURHENNE, J., MARTIN-FACKLAM, M., WEISS, J., VON WOLFF, M., STROWITZKI, T., WALTER-SACK, I. & HAEFELI, W.E. Oral contraception does not alter single dose saquinavir pharmacokinetics in women: 244
FUJIMURA, A. see TSURUOKA, S.
FUKAZAWA, I., UCHIDA, N., UCHIDA, E. & YASUHARA, H. Effects of grapefruit juice on pharmacokinetics of atorvastatin and pravastatin in Japanese: 448
GALBRAITH, K.J. see DOOLEY, M.J.
GALLAI, V. see DEPLANQUE, D.
GAN, S.H., ISMAIL, R., WAN ADNAN, W.A., ZULMI, W., KUMARASWAMY, N. & LARMIE, E.T. Relationship between Type A and B personality and debrisoquine hydroxylation capacity: 785
GANS, R.O.B. see MOL, P.G.M.
GIBNEY, C.A. see FARRELL, J.
GILLIS, D. see DAVIES, B.J.L.
GLEESON, M. see ZAHIR, H.
GOETTSCH, W.G. see MANTEL-TEEUWISSE, A.K.
GOGGIN, T., NGUYEN, Q.T.X. & MUNAFO, A. Population pharmacokinetic modelling of Emfilermin (recombinant human leukaemia inhibitory factor, r-hLIF) in healthy postmenopausal women and in infertile patients undergoing in vitro fertilization and embryo transfer: 576
GONZALES, C.R. see HUA, T.C.
GORSKI, J.C. see MACFADYEN, R.J.
GRAHAME-SMITH, D.G., ARONSON, J.K. Oxford Textbook of Clinical Pharmacology and Drug Therapy: 112
GRANFORS, M.T., BACKMAN, J.T., LAITILA, J. & NEUVONEN, P.J. Tizanidine is mainly metabolized by cytochrome P450 1A2 in vitro: 349
GREENHAFF, P.L., CAMPBELL-O’SULLIVAN, S.P., CONSTANTIN-TEODOSIU, D., POUCHER, S.M., ROBERTS, P.A. & TIMMONS, J.A. Metabolic inertia in contracting skeletal muscle: a novel approach for pharmacological intervention in peripheral vascular disease: 237
GREVING, J.P., DENIG, P., VAN DER VEEN, W.J., BELTMAN, F.W., STURKENBOOM, M.C.J.M. & HAAIJER-RUSKAMP, F.M. Trends in antihypertensive drug prescribing in dutch general practice from 1996 to 2000: 359
GRIEP, E.N. see VAN ROON, E.N.
GRIFFIN. J.P. & O’GRADY, J. The Regulation of Medical Products: 113
GRIND, M. see JOHNSTON, D.
GROENEVELD, G.J. see VAN KAN, H.J.M.
GROWCOTT, J. see CANTARINI, M.V.
GUCHELAAR, H.J. see MERKUS, P.
GUCHELAAR, H.J. see VAN KAN, H.J.M.
GUILLAUME, C. see REIJNTJENS, S.
HAAIJER-RUSKAMP, F.M. see DENIG, P.
HAAIJER-RUSKAMP, F.M. see GREVING, J.P.
HAAIJER-RUSKAMP, F.M. see MOL, P.G.M.
HAEFELI, W.E. see FRÖHLICH, M.
HAEFELI, W.E. see MARTIN-FACKLAM, M.
HAEFELI, W.E. see WEISS, J.
HALL, I.P. see LEE, D.K.C.
HAMMARLUND-UDENAES, M. see EDEROTH, P.
HAMRÉN, B. see JOHNSTON, D.
HANNAFORD, P.J. see SIMPSON, C.R.
HARADA, K. see TSURUOKA, S.
HARRIS, P.A. see DISHY, V.
HARTKOORN, R.C., CHANDLER, B., KHOO, S. & BACK, D.J. The interaction between anti-tuberculosis drugs and P-glycoprotein: 676
HARVEY, B.H. see BRINK, C.B.
HEATHMAN, M. see SKINNER, M.H.
HEIKKILÄ, A. see ANTILA, S.
HEINZERLING, H. see KAMERLING, I.M.C.
HEKSTER, Y.A. see WILTING, I.
HELMS, P.J. see KRISHNAMOORTHY, N.
HELMS, P.J. see NOVAK, P.
HELMS, P.J. see TANAKA, M.
HERING, W. see IHMSEN, H.
HERINGS, R.M.C. see MANTEL-TEEUWISSE, A.K.
HERINGS, R.M.C. see SCHOOFS, M.W.C.J.
HESSELINK, D.A., VAN SCHAIK, R.H.N., SMAK GREGOOR, P.J.H., WEIMAR, W. & VAN GELDER, T. Tacrolimus, but not cyclosporine, dose requirement is correlated with CYP3A5*3 and CYP3A4*1B genotype: 359
HEWITT, S. see HUNG, T.-Y.
HEYDARI, A., ROSTAMI-HODJEGAN, A., ROWLAND-YEO, K., LENNARD, M.S. & TUCKER, G.T. Methadone is not a mechanism-based inhibitor of cytochrome P450 2D6: 687
HISHIDA, A. see OHASHI, N.
HOFFER, C. see KHARASCH, E.D.
HOFMAN, A. see MAITLAND-VAN DER ZEE, A.H.
HOFMAN, A. see SCHOOFS, M.W.C.J.
HOFMAN, A. see VISSER, L.E.
HOIZEY, G. see FRANCES, C.
HOLBROOK, A. see WILSON, A.M.
HOLGATE, S. see NORRIS, V.
HORINAKA, S. see MINAMI, J.
HOROWITZ, J.D. see DAVIES, B.J.L.
HOROWITZ, J.D. see JONES, T.E.
HOUSTON, J.B. see ITO, K.
HOUTMAN, P.M. see VAN ROON, E.N.
HOVSEPIAN, L. see KÅGEDAL, M.
HUA, T.C., PAN, A., CHAN, C., POO, Y.K., SKINNER, M.H., KNADLER, M.P., GONZALES, C.R. & WISE, S.D. Effect of duloxetine on tolterodine pharmacokinetics in healthy volunteers: 652
HUGHES, A.M. see CANTARINI, M.V.
HUITEMA, A.D.R. see CROMMENTUYN, K.M.L.
HUITEMA, A.D.R. see DE JONGE, M.E.
HULL, R. see BOYCE, M.
HUNG, T.-Y. see KARUNAJEEWA, H.
HUNG, T.-Y., DAVIS, T.M.E., ILETT, K.F., KARUNAJEEWA, H., HEWITT, S., DENIS, M.B., LIM, C. & SOCHEAT, D. Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria: 253
HUSSEIN, Z. see PITSIU, M.
HUTCHINSON, M.R., MENELAOU, A., FOSTER, D.J.R., COLLER, J.K. & SOMOGYI, A.A. CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes: 287
IHMSEN, H., ALBRECHT, S., HERING, W., SCHÜTTLER, J. & SCHWILDEN, H. Modelling acute tolerance to the EEG effect of two benzodiazepines: 153
ILETT, K.F. see BATTY, K.T.
ILETT, K.F. see HUNG, T.-Y.
ILETT, K.F. see KARUNAJEEWA, H.
INOUE, Y. see YASUI-FURUKORI, N.
ISHIMITSU, T. see MINAMI, J.
ISMAIL, R. see GAN, S.H.
ITO, K., BROWN, H.S. & HOUSTON, J.B. Database analyses for the prediction of in vivo drug–drug interactions from in vitro data: 473
IVESON, E. see RAMBARAN, C.
JACKSON, C.M. see LEE, D.K.C.
JACKSON, P.R. see KHAWAJA, M.
JACKSON, S.H.D. see FORD, G.A.
JACKSON, S.H.D. see MANGONI, A.A.
JACKSON, S.H.D., MANGONI, A.A. & BATTY, G.M. Optimization of drug prescribing: 231
JAMES, H.M. see DAVIES, B.J.L.
JANSEN, T.L.TH.A. see VAN ROON, E.N.
JAUSSAUD, R. see TRENQUE, T.
JEWELL, R.C. see KUPPENS, I.E.L.M.
JIANG, B. see RAMBARAN, C.
JIANG, X., WILLIAMS, K.M., LIAUW, W.S., AMMIT, A.J., ROUFOGALIS, B.D., DUKE, C.C., DAY, R.O. & MCLACHLAN, A.J. Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects: 592
JOHNSON, P.J. see PURKINS, L.
JOHNSON, T.N., ROSTAMI-HODJEGAN, A. & TUCKER, G.T. A comparison of methods to predict drug clearance in neonates, infants and children: 677
JOHNSTON, D., GRIND, M., HAMRÉN, B., BÅÅTHE, S., WOLLBRATT M. & ERIKSSON U.G. Pharmacokinetics of melagatran after oral dosing with ximelagatran in patients with nonvalvular atrial fibrillation: 685
JOHNSTON, N.R. see CRUDEN, N.L.
JONES, T.E., MORRIS, R.G. & HOROWITZ, J.D. Concentration-time profile for perhexiline and hydroxyperhexiline in patients at steady state: 263
JOUKHADAR, C. see BELLMANN, R.
KÅGEDAL, M., DUVAUCHELLE, T., HOVSEPIAN, L., CHARLESWORTH, B.R., SU, H.-L. & YATES, R. Zolmitriptan demonstrates good pharmacokinetic consistency between and within individuals following intranasal administration: 679
KAJOSAARI, L.I. see NIEMI, M.
KALAÇA, S. see AKICI, A.
KALRA, L. see RAMBARAN, C.
KAMALI, F., KHAN, T.I., KING, B.P., FREARSON, R., KESTEVEN, P., WOOD, P., DALY, A.K. & WYNNE, H. The impact of patient age and genetic polymorphism of CYP2C9 on warfarin dose requirements: 668
KAMERLING, I.M.C., VAN HAARST, A.D., BURGGRAAF, J., SCHOEMAKER, R.C., DE KAM, M.L., HEINZERLING, H., COHEN, A.F. & MASCLEE, A.A.M. Effects of a nonpeptide motilin receptor antagonist on proximal gastric motor function: 393
KAMMERER, D. see STRACHAN, E.M.
KANAMARU, M. see OHASHI, N.
KANEKO, S. see YASUI-FURUKORI, N.
KARAALP, A. see AKICI, A.
KARAKUS, A. see KUPPENS, I.E.L.M.
KARLSSON, M.O. see KERBUSCH, T.
KARUNAJEEWA, H. see HUNG, T.-Y.
KARUNAJEEWA, H., LIM, C., HUNG, T.-Y., ILETT, K.F., DENIS, M.B., SOCHEAT, D. & DAVIS, T.M.E. Safety evaluation of fixed combination piperaquine plus dihydroartemisinin (Artekin®) in Cambodian children and adults with malaria: 93
KASBERGEN, A.A.H. see VISSER, L.E.
KASHANI, L. see AKHONDZADEH, S.
KASJE, W.N. see DENIG, P.
KASTELEIN, J.J.P. see MAITLAND-VAN DER ZEE, A.H.
KEESSEN, M. see DE JONGE, M.E.
KELLY, C.A. see STRACHAN, E.M.
KENNEDY, J. see CHUI, J.
KERBUSCH, T., MILLIGAN, P.A. & KARLSSON, M.O. Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population pharmacokinetic–pharmacodynamic data: 170
KERWIN, R. see TAYLOR, D.
KESTEVEN, P. see KAMALI, F.
KHAN, T.I. see KAMALI, F.
KHARASCH, E.D., HOFFER, C. & WHITTINGTON, D. The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone: 600
KHAWAJA, M. & JACKSON, P.R. Effect of patient information leaflet on drug preference: 688
KHOO, S. see HARTKOORN, R.C.
KING B.P. see DALY, A.K.
KING, B.P. see KAMALI, F.
KINGMA, J.H. see DENEER, V.H.M.
KINIRONS, M.T. & O’MAHONY, M.S. Drug metabolism and ageing: 540
KIRKESSELI, S. see NORRIS, V.
KIVIKKO, M. see ANTILA, S.
KLEIN, K. see COLLER, J.K.
KLUNGEL, O.H. see MAITLAND-VAN DER ZEE, A.H.
KLUNGEL, O.H. see MANTEL-TEEUWISSE, A.K.
KLUNGEL, O.H. see SCHELLEMAN, H.
KNADLER, M.P. see HUA, T.C.
KNADLER, M.P. see SKINNER, M.H.
KOBAYASHI, N. see MINAMI, J.
KOKWARO, G.O. see MITHWANI, S.
KONDO, T. see YASUI-FURUKORI, N.
KOOPMAN-KROON, C. see DE JONGE, M.E.
KOSHIKAWA, S. see OHASHI, N.
KOSTRZEWA, M. see MARTIN-FACKLAM, M.
KOVARIK, J.M., SCHMOUDER, R., BARILLA, D., WANG, Y. & KRAUS, G. Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects: 586
KRÄHENBÜHL, S. see WENK, M.
KRAMERS, C. see MULDER, J.
KRAUS, G. see KOVARIK, J.M.
KREBSFAENGER, N. see COLLER, J.K.
KRISHNAMOORTHY, N., EKINS-DAUKES, S., SIMPSON, C.R., OSMAN, M., TAYLOR, M., MILNE, R., HELMS, P.J. & MCLAY, J.S. Is the combined oral contraceptive pill associated with a reduction in the risk of asthma in teenage girls? A retrospective study in primary care: 665
KROMHOUT, D. see SCHELLEMAN, H.
KUAN, H.-Y. see SKINNER, M.H.
KUCHLING, G. see BELLMANN, R.
KUIJPERS, T.W. see CROMMENTUYN, K.M.L.
KUMANA, C.R. see CHEUNG, B.M.Y.
KUMARASWAMY, N. see GAN, S.H.
KUPPENS, I.E.L.M., RADEMA, S., ROSING, H., STOKVIS, E., SWART, M., JEWELL, R.C., RUSSO, M., KARAKUS, A., WITTEVEEN, E., BEIJNEN, J.H., VOEST, E.E. & SCHELLENS, J.H.M. A Phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF 120918) in combination with 2.0 mg oral topotecan in cancer patients: 360
KUPPENS, I.E.L.M., VAN MAANEN, M.J., ROSING, H., BOSCH, T.M., FITZPATRICK, A., BEIJNEN, J.H. & SCHELLENS, J.H.M. Oral bioavailability of docetaxel in combination with OC 144–093 (ONT-093): 360
KYRKLUND, C., BACKMAN, J.T., NEUVONEN, M. & NEUVONEN, P.J. Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects: 181
LACARELLE, B. see SOLAS, C.
LAFEUILLADE, A. see SOLAS, C.
LAITILA, J. see GRANFORS, M.T.
LARMIE, E.T. see GAN, S.H.
LASEUR, M. see MOL, P.G.M.
LATRY, P. see MARTIN, K.
LAU, C.-P. see CHEUNG, B.M.Y.
LAUDER, I.J. see CHEUNG, B.M.Y.
LAUGHLIN, M. see COURTNEY, R.
LAYTON, G. see SOBUE, S.
LEBRUN, S. see MALONNE, H.
LECLERC, V. see SOBUE, S.
LEE, D.K.C., BATES, C.E. & LIPWORTH, B.J. Acute systemic effects of inhaled salbutamol in asthmatic subjects expressing common homozygous β2-adrenoceptor haplotypes at positions 16 and 27: 100
LEE, D.K.C., CURRIE, G.P., HALL, I.P., LIMA, J.J. & LIPWORTH, B.J. The arginine-16 β2-adrenoceptor polymorphism predisposes to bronchoprotective subsensitivity in patients treated with formoterol and salmeterol: 68
LEE, D.K.C., JACKSON, C.M., SOUTAR, P.C., FARDON, T.C. & LIPWORTH, B.J. Effects of single or combined histamine H1-receptor and leukotriene CysLT1-receptor antagonism on nasal adenosine monophosphate challenge in persistent allergic rhinitis: 714
LEE, D.K.C. & LIPWORTH, B.J. The presence of emphysema does not affect the systemic bioactivity of inhaled fluticasone in severe chronic obstructive pulmonary disease: 388
LEHTONEN, L. see ANTILA, S.
LELORIER, J. see QUACH, C.
Lennard, L. see CARTWRIGHT, C.S.
LENNARD, M.S. see DAVIES, S.J.C.
LENNARD, M.S. see HEYDARI, A.
LEPEU, G. see SOLAS, C.
LEROUX, B. see TRENQUE, T.
LESLIE, S.J., RAHMAN, M.Q., DENVIR, M.A., NEWBY, D.E. & WEBB, D.J. Endothelins and their inhibition in the human skin microcirculation: ET[1–31], a new vasoconstrictor peptide: 720
LEUFKENS, H.G.M. see MAITLAND-VAN DER ZEE, A.H.
LEYS, D. see DEPLANQUE, D.
LIAUW, W.S. see JIANG, X.
LIE-A-HUEN, L. see DENEER, V.H.M.
LIGTHELM, R.J. see VAN RIEMSDIJK, M.M.
LIM, C. see HUNG, T.-Y.
LIM, C. see KARUNAJEEWA, H.
LIM, J. see COURTNEY, R.
LIMA, J.J. see LEE, D.K.C.
LIPWORTH, B.J. see LEE, D.K.C.
LOCKTON, J.A. see BLAKEY, G.E.
LOKE, Y.K., DERRY, S. & ARONSON, J.K. A comparison of three different sources of data in assessing the frequencies of adverse reactions to amiodarone: 616
LOKIEC F. see URIEN, S.
LOVE, E.R. see PURKINS, L.
LUNDBERG, C.J.F. see EDEROTH, P.
MACDONALD, T.M. see MORANT, S.V.
MACFADYEN, R.J., GORSKI, J.C., BRATER, D.C. & STRUTHERS, A.D. Furosemide responsiveness, non-adherence and resistance during the chronic treatment of heart failure: a longitudinal study: 622
MACLEOD, M.-J. see REID, J.
MAHAGERI, H. see AKHONDZADEH, S.
MAHMUD, A. & FEELY, J. Effects of passive smoking on blood pressure and aortic pressure waveform in healthy young adults – influence of gender: 37
MAHMUD, A. & FEELY, J. Vascular effects of amlodipine in essential hypertension: 684
MAHMUD, A. see MCNULTY, M.
MAITLAND-VAN DER ZEE, A.H., STRICKER, B.H.CH., KLUNGEL, O.H., KASTELEIN, J.J.P., HOFMAN, A., WITTEMAN, J.C.M., LEUFKENS, H.G.M., VAN DUIJN, C.M. & DE BOER, A. The effectiveness of HMG-COA reductase inhibitors is affected by ACE insertion deletion polymorphism: 361
MAJID, O. see MITHWANI, S.
MAJID, O. see PITSIU, M.
MALONNE, H., SONET, B., STREEL, B., LEBRUN, S., DE NIET, S., SERENO, A. & VANDERBIST, F. Pharmacokinetic evaluation of a new oral sustained release dosage form of tramadol: 270
MANGONI, A.A. see FORD, G.A.
MANGONI, A.A. see JACKSON, S.H.D.
MANGONI, A.A. & JACKSON, S.H.D. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications: 6
MANTEL-TEEUWISSE, A.K., GOETTSCH, W.G., KLUNGEL, O.H., DE BOER, A. & HERINGS, R.M.C. Determinants of persistence with statin use in daily medical practice: 361
MARSH, K. see MITHWANI, S.
MARTIN, K., BÉGAUD, B., LATRY, P., MIREMONT-SALAMÉ, G., FOURRIER, A. & MOORE, N. Differences between clinical trials and postmarketing use: 86
MARTIN, P. see MARTIN-FACKLAM, M.
MARTIN, P.D. see SIMONSON, S.G.
MARTIN-FACKLAM, M. see FRÖHLICH, M.
MARTIN-FACKLAM, M., KOSTRZEWA, M., MARTIN, P. & HAEFELI, W.E. Quality of drug information on the World Wide Web and strategies to improve pages with poor information quality. An intervention study on pages about sildenafil: 80
MAS, J.-L. see DEPLANQUE, D.
MASCLEE, A.A.M. see KAMERLING, I.M.C.
MATHÔT, R.A.A. see CROMMENTUYN, K.M.L.
MATHÔT, R.A.A. see DE JONGE, M.E.
MATSUOKA, H. see MINAMI, J.
MAXWELL, S.J.M. see PAYNE, R.A.
MAYER, B.X. see BELLMANN, R.
MCCAUGHAN, G. see ZAHIR, H.
MCGEECHAN, K. see ROUGHEAD, E.E.
MCLACHLAN, A.J. see BLAIR, E.Y.L.
MCLACHLAN, A.J. see JIANG, X.
MCLACHLAN, A.J. see SLAVIERO, K.A.
MCLACHLAN, A.J. see ZAHIR, H.
MCLAY, J.S. see KRISHNAMOORTHY, N.
MCLAY, J.S. see MCLNTYRE, C.
MCLAY, J.S. see NOVAK, P.
MCLAY, J.S. see TANAKA, M.
MCLNTYRE, C. & MCLAY, J.S. The relationship between self reported compliance with simvastatin and attainment of target lipid concentrations. A prospective study: 682
MCMAHON, A.D. see MORANT, S.V.
MCNULTY, M., MAHMUD, A. & FEELY, J. Matrix metalloproteinase-1, collagen turnover and increased aortic pulse wave velocity: 681
MENELAOU, A. see HUTCHINSON, M.R.
MERKUS, F.W.H.M. see MERKUS, P.
MERKUS, P., GUCHELAAR, H.J., BOSCH, D.A. & MERKUS, F.W.H.M. Nasal drug delivery to the cerebrospinal fluid: transport of a hydrophilic drug: 362
MEULENDIJKS, C. see MULDER, J.
MIHARA, K. see YASUI-FURUKORI, N.
MILLART, H. see FRANCES, C.
MILLART, H. see TRENQUE, T.
MILLET, S. see NORRIS, V.
MILLIGAN, P.A. see KERBUSCH, T.
MILNE, R. see KRISHNAMOORTHY, N.
MILNE, R. see NOVAK, P.
MINAMI, J., NUMABE, A., ANDOH, N., KOBAYASHI, N., HORINAKA, S., ISHIMITSU, T. & MATSUOKA, H. Comparison of once-daily nifedipine controlled-release with twice-daily nifedipine retard in the treatment of essential hypertension: 632
MINAR, E. see BELLMANN, R.
MIREMONT-SALAMÉ, G. see MARTIN, K.
MITCHELL, A. see WENZEL, R.R.
MITCHELL, P.D. see SIMONSON, S.G.
MITHWANI, S., AARONS, L., KOKWARO, G.O., MAJID, O., MUCHOHI, S., EDWARDS, G., MOHAMED, S., MARSH, K. & WATKINS, W. Population pharmacokinetics of artemether and dihydroartemisinin following single intramuscular dosing of artemether in African children with severe falciparum malaria: 146
MOHAMED, S. see MITHWANI, S.
MOHAMMADI, M.R. see AKHONDZADEH, S.
MOKHTARI, M. see SOLAS, C.
MOL, P.G.M., DENIG, P., NANNAN PANDAY, P.V., GANS, R.O.B., DEGENER, J.E., LASEUR, M. & HAAIJER-RUSKAMP, F.M. When are antimicrobial treatment guidelines not followed?: 362
MOL, P.G.M., NANNAN PANDAY, P.V., DEGENER, J.E., VAN DER WERF, T.S., HAAIJER-RUSKAMP, F.M. & GANS, R.O.B. Academic fluoroquinolone prescribing, resistance and impact of guidelines: 363
MONSTER, T.B.M. see ATTHOBARI, J.
MOOLENAAR, M. see WILTING, I.
MOORE, N. see MARTIN, K.
MOORE, P.K. see RANG, H.P.
MORANT, S.V., MCMAHON, A.D., CLELAND, J.G.F., DAVEY, P.G. & MACDONALD, T.M. Cardiovascular prophylaxis with aspirin: costs of supply and management of upper gastrointestinal and renal toxicity: 188
MOREAU, J. see SOLAS, C.
MORRIS, R.G. see DAVIES, B.J.L.
MORRIS, R.G. see JONES, T.E.
MORTIER, E.P. see STRUYS, M.M.R.F.
MOTTRAM, D.R. see CHESTER, N.
MOURAD, L. see VAN ROON, E.N.
MOVIG, K.L.L. see WILTING, I.
MOZAYANI, E.A. & RAYMON, L.P. Handbook of Drug Interactions. A Clinical and Forensic Guide: 818
MÜLLER, M. see BELLMANN, R.
MÜRDTER, T.E. see COLLER, J.K.
MUCHOHI, S. see MITHWANI, S.
MULDER, J., MEULENDIJKS, C., NEEF, C., NATSCH, S. & KRAMERS, C. Reliability of reported ingestion in paracetamol overdose: 364
MUNAFO, A. see GOGGIN, T.
NACAK, M. see AYNACIOGLU, A.S.
NAGASHIMA, S. see OHASHI, N.
NAISBITT, D.J. see FARRELL, J.
NAISBITT, D.J. see WU, Y.
NAISBITT, D.J., FARRELL, J., CHAMBERLAIN, P.J., PARK, B.K. & PIRMOHAMED, M. Characterization of T-cell responses in phenindione hypersensitivity: 675
NAISBITT, D.J., WU, Y., FARRELL, J., O’NEILL, P.M., PIRMOHAMED, M. & PARK, B.K. T-cell recognition of carbamazepine and carbamazepine metabolites: 669
NAKAGAMI, T. see YASUI-FURUKORI, N.
NAND, R.A. see ZAHIR, H.
NANNAN PANDAY, P.V. see MOL, P.G.M.
NATSCH, S. see MULDER, J.
NEEF, C. see MULDER, J.
NENTWICH, H. see BOYCE, M.
NEUHAUS, P. see COLLER, J.K.
NEUVONEN, M. see KYRKLUND, C.
NEUVONEN, M. see NIEMI, M.
NEUVONEN, P.J. see GRANFORS, M.T.
NEUVONEN, P.J. see KYRKLUND, C.
NEUVONEN, P.J. see NIEMI, M.
NEWBY, D.E. see CRUDEN, N.L.
NEWBY, D.E. see LESLIE, S.J.
NGUYEN, Q.T.X. see GOGGIN, T.
NIEMAN, F.H.M. see REIJNTJENS, S.
NIEMI, M., KAJOSAARI, L.I., NEUVONEN, M., BACKMAN, J.T. & NEUVONEN, P.J. The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects: 441
NISHIKI, K. see TSURUOKA, S.
NORDSTRÖM, C.-H. see EDEROTH, P.
NORRIS, V. see BOYCE, M.
NORRIS, V., CHOONG, L., TRAN, D., CORDEN, Z., BOYCE, M., ARSHAD, S., HOLGATE, S., O’CONNOR, B., MILLET, S. & KIRKESSELI, S. A placebo controlled, double-blind, crossover study of 8 days treatment with IVL745, a VLA-4 antagonist, in mild atopic asthma: 676
NORWOOD, P. see BLAKEY, G.E.
NOVAK, P., EKINS-DAUKES, S., SIMPSON, C.R., TAYLOR, M., MILNE, R., HELMS, P.J. & MCLAY, J.S. Acute prescribing in general practice to children on longterm antiepiletic therapy. The potential for acute drug-drug interactions. A retrospective observational study: 666
NÜSSLER, A. see COLLER, J.K.
NUMABE, A. see MINAMI, J.
ÖZDEMIR, M., AKTAN, Y., ROSTAMI-HODJEGAN, A., CREWE, H.K. & TUCKER, G.T. Assessment of CYP2D6 in vivo activity: relative sensitivity of urinary metabolic ratios of debrisoquine (DB), dextromethorphan (DM) and metoprolol (MP) to urine pH: 686
O’BRIEN, L. see SKINNER, M.H.
O’CONNOR, B. see NORRIS, V.
O’CONNOR, H. see BENNETT, K.
O’GRADY, J. see GRIFFIN. J.P.
O’GRADY, J. see SINZINGER, H.
O’MAHONY, M.S. see KINIRONS, M.T.
O’MAHONY, M.S. see ROUTLEDGE, P.A.
O’MORAIN, C. see BENNETT, K.
O’NEILL, P.M. see NAISBITT, D.J.
ODUBANJO, E., BENNETT, K. & FEELY, J. Is the quality of prescribing in the elderly related to socio-economic status?: 665
ODUBANJO, E., BENNETT, K. & FEELY, J. Prescribing of antidepressants in patients with recent onset and existing ischaemic heart disease in general practice: 680
ODUBANJO, E., BENNETT, K. & FEELY, J. Variation in the prescribing of antidepressants, anxiolytics, hypnotics and sedatives in general practice: 679
OHASHI, N., UEMATSU, T., NAGASHIMA, S., KANAMARU, M., TOGAWA, A., HISHIDA, A., UCHIDA, E., AKIZAWA, T. & KOSHIKAWA, S. The calcimimetic agent KRN 1493 lowers plasma parathyroid hormone and ionized calcium concentrations in patients with chronic renal failure on haemodialysis both on the day of haemodialysis and on the day without haemodialysis: 726
OKTAY, Ş. see AKICI, A.
OLIVER, D.W. see BRINK, C.B.
OLIVER, J.J. see ATTINÀ, T.
OLIVER, J.J., BEUDEKER, Q.H., CATE, T.T., BOWLER, A. & WEBB, D.J. The dose-response relationship of sublingual GTN to brachial artery diameter and change in augmentation index: 673
OOSTERINK, B.J. see DUMONT, G.J.H.
OOSTVOGEL, P.M. see BARTELINK, I.H.
OSMAN, M. see KRISHNAMOORTHY, N.
OVERBOSCH, D. see VAN RIEMSDIJK, M.M.
OVERDIEK, J.W.P.M. see BARTELINK, I.H.
OWEN, R.J. see BJARNASON, I.T.
OXLADE, N. see BJARNASON, I.T.
PALTANSING, S. see DUMONT, G.J.H.
PAN, A. see HUA, T.C.
PARK, B.K. see FARRELL, J.
PARK, B.K. see NAISBITT, D.J.
PARK, B.K. see WU, Y.
PARNETTI, L. see DEPLANQUE, D.
PATON, C. see TAYLOR, D.
PAYNE, R.A., SYMEONIDE, C.N., MAXWELL, S.J.M. & WEBB. D.J. Pulse transit time measured from the ECG as a marker of beat-to-beat blood pressure: 691
PENNING-VAN BEEST, F.J.A. see VISSER, L.E.
PENTIKÄINEN, P.J. see ANTILA, S.
PERRETT, J. see BLAKEY, G.E.
PERSKY, A.M., BERRY, N.S., POLLACK, G.M. & BROUWER, K.L.R. Modelling the cardiovascular effects of ephedrine: 552
PETIT, N. see SOLAS, C.
PHILIPP, T. see WENZEL, R.R.
PIERCE, R. see DISHY, V.
PINON, J.-M. see TRENQUE, T.
PIRMOHAMED, M. see FARRELL, J.
PIRMOHAMED, M. see NAISBITT, D.J.
PIRMOHAMED, M. see WU, Y.
PITSIU, M., HUSSEIN, Z., MAJID, O., AARONS, L., DE LONGUEVILLE, M. & STOCKIS, A. Retrospective population pharmacokinetic analysis of cetirizine in children aged 6 months to 12 years: 402
PLUME, J. see BLAKEY, G.E.
POHJANJOUSI, P. see ANTILA, S.
POIZOT-MARTIN, I. see SOLAS, C.
POLLACK, G.M. see PERSKY, A.M.
POLS, H.A.P. see SCHOOFS, M.W.C.J.
POO, Y.K. see HUA, T.C.
PORTNER, R., WILSON, C., YEO, K.R. & YEO, W.W. In-patient initiation of warfarin treatment: an audit: 668
POSNER, J. see CALDER, N.
POUCHER, S.M. see GREENHAFF, P.L.
POWELL, M. see CHESTER, N.
PRASAD, H.C. see DISHY, V.
PRATT, P. see DAVIES, S.J.C.
PRICE, A.B. see BJARNASON, I.T.
PROOST, J.H. see DENEER, V.H.M.
PURKINS, L., LOVE, E.R., EVE, M.D., WOOLDRIDGE, C.L., COWAN, C., SMART, T.S., JOHNSON, P.J. & RAPEPORT, W.G. The influence of diet upon liver function tests and serum lipids in healthy male volunteers resident in a Phase I unit: 199
QUACH, C., COLLET, J.-P. & LELORIER, J. Acute otitis media in children: a retrospective analysis of physician prescribing patterns: 500
QUASIM, A. see BENNETT, K.
QUEREUX, C. see TRENQUE, T.
RADEMA, S. see KUPPENS, I.E.L.M.
RADWANSKI, E. see COURTNEY, R.
RAHMAN, M.Q. see LESLIE, S.J.
RALPH, L.D., THOMSON, A.H., DOBBS, N.A. & TWELVES, C. Maximum a posteriori Bayesian estimation of epirubicin clearance by limited sampling: 764
RAMBARAN, C., IVESON, E., WILLIAMS, I.L., JIANG, B., CHOWIENCZYK, P.J., RITTER, J.M., SHAH, A.M., FORRESTER, T. & KALRA, L. Relation between β2-adrenoceptor responsiveness assessed by pulse wave analysis and flow mediated dilation: 675
RANG, H.P., DALE, M.M. RITTER, J.M. & MOORE, P.K. Pharmacology, 5th edn: 112
RAPEPORT, W.G. see PURKINS, L.
RAVAUX, I. see SOLAS, C.
RAYMON, L.P. see MOZAYANI, E.A.
RÉMY, G. see TRENQUE, T.
REDDY, S. see SKINNER, M.H.
REID, J., MACLEOD, M.-J. & WILLIAMS, D. Timing of aspirin use in acute stroke and use of secondary prevention: stroke unit vs medical unit: 673
REIJNTJENS, S., GUILLAUME, C., STOLK, L., DEGRAEUWE, P.L.J., NIEMAN, F.H.M. & DE BOER, A. Amoxicillin pharmacokinetics in (pre) term neonates: 364
REILLY, T. see CHESTER, N.
REITH, D. see CHUI, J.
REMON, J.P. see VAN DEN ABEELE, W.M.
REUCK, J.D. see DEPLANQUE, D.
RITTER, J.M. see BRETT, S.E.; RAMBARAN, C.
RITTER, J.M. see RANG, H.P.
RIVORY, L.P. see BLAIR, E.Y.L.
RIVORY, L.P. see SLAVIERO, K.A.
ROBERTS, P.A. see GREENHAFF, P.L.
RODENHUIS, S. see DE JONGE, M.E.
RONGEN, MD, PHD, G.A. see VAN GINNEKEN, MD, E.E.M.
ROOTS, I. see AYNACIOGLU, A.S.
ROSING, H. see DE JONGE, M.E.
ROSING, H. see KUPPENS, I.E.L.M.
ROSTAMI-HODJEGAN, A. see HEYDARI, A.
ROSTAMI-HODJEGAN, A. see JOHNSON, T.N.
ROSTAMI-HODJEGAN, A. seeÖZDEMIR, M.
ROSTAMI-HODJEGAN, A. see ROWLAND YEO, K.
ROUFOGALIS, B.D. see JIANG, X.
ROUGHEAD, E.E., MCGEECHAN, K. & SAYER, G.P. Bisphosphonate use and subsequent prescription of acid suppressants: 813
ROUTLEDGE, P.A., O’MAHONY, M.S. & WOODHOUSE, K.W. Adverse drug reactions in elderly patients: 121
ROWLAND YEO, K. see BECK, C.R.
ROWLAND YEO, K., ROSTAMI-HODJEGAN, A. & TUCKER, G.T. Abundance of cytochromes P450 in human liver: a meta-analysis: 687
ROWLAND-YEO, K. see HEYDARI, A.
RUSSELL, M. see BLAKEY, G.E.
RUSSO, M. see KUPPENS, I.E.L.M.
SALLUSTIO, B.C. see DAVIES, B.J.L.
SASTRE TORAŇO, J. see VAN KAN, H.J.M.
SAVAGE, C.M. see CARTWRIGHT, C.S.
SAYER, G.P. see ROUGHEAD, E.E.
SCHÄFERS, R.F. see WENZEL, R.R.
SCHAARS, C.F. see DENIG, P.
SCHELLEMAN, H., KLUNGEL, O.H., VERSCHUREN, W.M.M., DE BOER, A., STRICKER, B.H.CH. & KROMHOUT, D. Prevalence and determinants of undertreatment of hypertension in the Netherlands: 365
SCHELLENS, J.H.M. see DE JONGE, M.E.
SCHELLENS, J.H.M. see KUPPENS, I.E.L.M.
SCHERPBIER, H.J. see CROMMENTUYN, K.M.L.
SCHMIDT, R. see DEPLANQUE, D.
SCHMOUDER, R. see KOVARIK, J.M.
SCHNECK, D.W. see SIMONSON, S.G.
SCHOEMAKER, R. see DUMONT, G.J.H.
SCHOEMAKER, R.C. see KAMERLING, I.M.C.
SCHOOFS, M.W.C.J., VAN DER KLIFT, M., HOFMAN, A., DE LAET, C.E.D.H., HERINGS, R.M.C., POLS, H.A.P. & STRICKER, B.H.CH. Thiazide diuretics and the risk of hip fracture: 365
SCHÜTTLER, J. see IHMSEN, H.
SCHWILDEN, H. see IHMSEN, H.
SCIBERRAS, D. see CALDER, N.
SEGER, M.E. see SKINNER, M.H.
SERENO, A. see MALONNE, H.
SHAH, A.M. see RAMBARAN, C.
SIFFERT, W. see WENZEL, R.R.
SIMON, N. see TRENQUE, T.
SIMONSON, S.G., MARTIN, P.D., WARWICK, M.J., MITCHELL, P.D. & SCHNECK, D.W. The effect of rosuvastatin on oestrogen & progestin pharmacokinetics in healthy women taking an oral contraceptive: 279
SIMPSON, C.R. see KRISHNAMOORTHY, N.
SIMPSON, C.R. see NOVAK, P.
SIMPSON, C.R., HANNAFORD, P.J. & WILLIAMS, D. Gender and age differences in the secondary prevention of coronary heart disease in Scotland: a cross sectional study using primary care data: 672
SINZINGER, H. & O’GRADY, J. Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems: 525
SKERJANEC, A. see SKINNER, M.H.
SKINNER, M.H. see HUA, T.C.
SKINNER, M.H., KUAN, H.-Y., SKERJANEC, A., SEGER, M.E., HEATHMAN, M., O’BRIEN, L., REDDY, S. & KNADLER, M.P. Effect of age on the pharmacokinetics of duloxetine in women: 54
SLAVIERO, K.A., CLARKE, S.J., MCLACHLAN, A.J., BLAIR, E.Y.L. & RIVORY, L.P. Population pharmacokinetics of weekly docetaxel in patients with advanced cancer: 44
SMAK GREGOOR, P.J.H. see HESSELINK, D.A.
SMART, T.S. see PURKINS, L.
SMITS, MD, PHD, P. see VAN GINNEKEN, MD, E.E.M.
SOBUE, S., TAN, K., LAYTON, G., LECLERC, V. & WEIL, A. The effects of renal impairment on the pharmacokinetics and safety of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole: 773
SOCHEAT, D. see HUNG, T.-Y.
SOCHEAT, D. see KARUNAJEEWA, H.
SOFOWORA, G. see DISHY, V.
SOLAS, C., POIZOT-MARTIN, I., DROGOUL, M.-P., RAVAUX, I., DHIVER, C., LAFEUILLADE, A., ALLEGRE, T., MOKHTARI, M., MOREAU, J., LEPEU, G., PETIT, N., DURAND, A. & LACARELLE, B. Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor: 436
SOMOGYI, A.A. see DAVIES, B.J.L.
SOMOGYI, A.A. see FOSTER, D.J.R.
SOMOGYI, A.A. see HUTCHINSON, M.R.
SONET, B. see MALONNE, H.
SOUTAR, P.C. see LEE, D.K.C.
SPIEKSMA, M. see VAN KAN, H.J.M.
STEIN, C.M. see DISHY, V.
STOCKIS, A. see PITSIU, M.
STOKVIS, E. see KUPPENS, I.E.L.M.
STOLK, L. see REIJNTJENS, S.
STRACHAN, E.M., KAMMERER, D., KELLY, C.A. & BATEMAN, D.N. Electrocardiograph and haemodynamic changes in thioridazine and chlorpromazine overdose: 678
STRACK VAN SCHIJNDEL, R.M.J. see SWART, E.L.
STREEL, B. see MALONNE, H.
STRICKER, B.H. see VAN RIEMSDIJK, M.M.
STRICKER, B.H. see VISSER, L.E.
STRICKER, B.H.CH. see MAITLAND-VAN DER ZEE, A.H.
STRICKER, B.H.CH. see SCHELLEMAN, H.
STRICKER, B.H.CH. see SCHOOFS, M.W.C.J.
STRICKER, B.H.CH. see VISSER, L.E.
STROWITZKI, T. see FRÖHLICH, M.
STRUTHERS, A.D. see MACFADYEN, R.J.
STRUYS, M.M.R.F., VEREECKE, H.E.M. & MORTIER, E.P. Electro-encephalographic surrogate measures fail to describe the pharmacodynamic interaction between ketamine and propofol: 366
STURKENBOOM, M.C.J.M. see GREVING, J.P.
STURKENBOOM, M.C.J.M. see VAN RIEMSDIJK, M.M.
STUURMAN, A. see DENEER, V.H.M.
SU, H.-L. see KÅGEDAL, M.
SUGIMOTO, K. see TSURUOKA, S.
SUZUKI, A. see YASUI-FURUKORI, N.
SWART, E.L., ZUIDEVELD, K.P., DE JONGH, J., DANHOF, M., THIJS, L.G. & STRACK VAN SCHIJNDEL, R.M.J. Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients: 135
SWART, M. see KUPPENS, I.E.L.M.
SYMEONIDE, C.N. see PAYNE, R.A.
TAKAHATA, T. see YASUI-FURUKORI, N.
TAN, K. see SOBUE, S.
TANAKA, M., EKINS-DAUKES, S., HELMS, P.J. & MCLAY, J.S. Off label drug use in children. A prospective questionnaire assessment of attitudes amongst scottish hospital based paediatricians: 677
TATEISHI, T. see YASUI-FURUKORI, N.
TAYLOR, D., PATON, C. & KERWIN, R. The Maudsley 2003 Prescribing Guidelines, 7th edition: 661
TAYLOR, G.R. see DOOLEY, M.J.
TAYLOR, M. see KRISHNAMOORTHY, N.
TAYLOR, M. see NOVAK, P.
TAYLOR, S. Quinine intoxications: a continuing problem: 817
TEELING, M. see USHER, C.
TEELING, M., BENNETT, K. & FEELY, J. Have clinical guidelines on use of statins been implemented in primary care?: 671
TEELING, M., BENNETT, K. & FEELY, J. Have COX-2 inhibitors influenced the co-prescription of anti-ulcer drugs with NSAIDs?: 337
TEHRANIDOOST, M. see AKHONDZADEH, S.
THABANE, L. see WILSON, A.M.
THIJS, L.G. see SWART, E.L.
THOMSON, A.H. see RALPH, L.D.
THORNTON, O. see BENNETT, K.
TIBBOEL, D. see ALLEGAERT, K.
TIMMONS, J.A. see GREENHAFF, P.L.
TOBI, H. see VAN ROON, E.N.
TODESCO, L. see WENK, M.
TOGAWA, A. see OHASHI, N.
TORDOFF, J. see CHUI, J.
TRAN, D. see NORRIS, V.
TRENQUE, T. see FRANCES, C.
TRENQUE, T., SIMON, N., VILLENA, I., CHEMLA, C., QUEREUX, C., LEROUX, B., JAUSSAUD, R., RÉMY, G., DUPOUY, D., MILLART, H., PINON, J.-M. & URIEN, S. Population pharmacokinetics of pyrimethamine and sulfadoxine in children with congenital toxoplasmosis: 735
TSURUOKA, S., WAKAUMI, M., NISHIKI, K., ARAKI, N., HARADA, K., SUGIMOTO, K. & FUJIMURA, A. Subclinical alteration of taste sensitivity induced by candesartan in healthy subjects: 807
TUCKER, G.T. see HEYDARI, A.
TUCKER, G.T. see JOHNSON, T.N.
TUCKER, G.T. seeÖZDEMIR, M.
TUCKER, G.T. see ROWLAND YEO, K.
TULEN, J.H.M. see VAN RIEMSDIJK, M.M.
TUNBLAD, K. see EDEROTH, P.
TURNER, C. see BRETT, S.E.
TWELVES, C. see RALPH, L.D.
UCHIDA, E. see FUKAZAWA, I.
UCHIDA, E. see OHASHI, N.
UCHIDA, N. see FUKAZAWA, I.
UEMATSU, T. see OHASHI, N.
UGURLU, M.Ü. see AKICI, A.
UNGERSTEDT, U. see EDEROTH, P.
URIEN, S. & LOKIEC F. Population pharmacokinetics of total and unbound plasma cisplatin in adult patients: 756
URIEN, S. see TRENQUE, T.
USHER, C., BENNETT, K. & FEELY, J. Adherence to treatment in older people in primary care – a nested case control study: 680
USHER, C., TEELING, M., BENNETT, K. & FEELY, J. Effect of the Women's Health Initiative trial on hormone replacement therapy prescribing: 667
UYTDEHAAG, G.M.M. see DENEER, V.H.M.
VAN ASSELT, G.J. see BARTELINK, I.H.
VAN BORTEL, L.M. see VAN DEN ABEELE, W.M.
VAN BURGEL, N. see DUMONT, G.J.H.
VAN DEN ABEELE, W.M., DE BRABANDER, C., VERVAET, C., REMON, J.P. & VAN BORTEL, L.M. Bioavailability of ibuprofen from hot-melt extruded mini-matrices: 366
VAN DEN BERG, L.H. see VAN KAN, H.J.M.
VAN DEN BONGARD, H.J.G.D. see DE JONGE, M.E.
VAN DEN BROEK, P. see VAN GINNEKEN, MD, E.E.M.
VAN DER KLIFT, M. see SCHOOFS, M.W.C.J.
VAN DER LINDEN, M. see DUMONT, G.J.H.
VAN DER VEEN, W.J. see GREVING, J.P.
VAN DER WERF, T.S. see MOL, P.G.M.
VAN DUIJN, C.M. see MAITLAND-VAN DER ZEE, A.H.
VAN DUIJN, C.M. see VISSER, L.E.
VAN GELDER, T. see HESSELINK, D.A.
VAN GERVEN, J.M.A. see DUMONT, G.J.H.
VAN GERVEN, J.M.A. see FRANSON, K.L.
VAN GIERSBERGEN, P.L.M. see DINGEMANSE, J.
VAN GINNEKEN, MD, E.E.M., VAN DEN BROEK, P., SMITS, MD, PHD, P. & RONGEN, MD, PHD, G.A. Human adenosine kinetics measured by microdialysis: 367
VAN HAARST, A.D. see KAMERLING, I.M.C.
VAN HEESWIJK, R.P.G. see CROMMENTUYN, K.M.L.
VAN HEMEL, N.M. see DENEER, V.H.M.
VAN KAN, H.J.M., GROENEVELD, G.J., SASTRE TORAŇO, J., SPIEKSMA, M., VAN DEN BERG, L.H. & GUCHELAAR, H.J. Correlation between riluzole clearance and CYP1A2 activity in patients with amyotrophic lateral sclerosis: 367
VAN MAANEN, M.J. see KUPPENS, I.E.L.M.
VAN MAANEN, R. see DE JONGE, M.E.
VAN RIEMSDIJK, M.M., STURKENBOOM, M.C.J.M., DITTERS, J.M., TULEN, J.H.M., LIGTHELM, R.J., OVERBOSCH, D. & STRICKER, B.H. Low body mass index is associated with an increased risk of neuropsychiatric adverse events and concentration impairment in women on mefloquine: 506
VAN ROON, E.N., JANSEN, T.L.TH.A., MOURAD, L., HOUTMAN, P.M., BRUYN, G.A.W., GRIEP, E.N., WILFFERT, B., TOBI, H. & BROUWERS, J.R.B.J. Leflunomide in active rheumatoid arthritis: a prospective study in daily practice: 790
VAN SCHAIK, R.H.N. see HESSELINK, D.A.
VAN SCHAIK, R.H.N. see VISSER, L.E.
VAN VLIET, M. see VISSER, L.E.
VAN ZANDWIJK, N. see DE JONGE, M.E.
VANDERBIST, F. see MALONNE, H.
VANMOLKOT, F.H.M. & DE HOON, J.N.J.M. Calcitonin gene-related peptide-induced vasodilation in the human forearm: inhibition by the CGRP-receptor antagonist CGRP8–37: 368
VENTER, D.P. see BRINK, C.B.
VERBESSELT, R. see ALLEGAERT, K.
VEREECKE, H.E.M. see STRUYS, M.M.R.F.
VERSCHUREN, W.M.M. see SCHELLEMAN, H.
VERVAET, C. see VAN DEN ABEELE, W.M.
VILLENA, I. see TRENQUE, T.
VISSER, L.E., PENNING-VAN BEEST, F.J.A., WILSON, J.H.P., VULTO, A.G., KASBERGEN, A.A.H., DE SMET, P.A.G.M., HOFMAN, A. & STRICKER, B.H. Overanticoagulation associated with combined use of lactulose and acenocoumarol or phenprocoumon: 522
VISSER, L.E., VAN VLIET, M., VAN SCHAIK, R.H.N., KASBERGEN, A.A.H., DE SMET, P.A.G.M., VULTO, A.G., HOFMAN, A., VAN DUIJN, C.M. & STRICKER, B.H.CH. The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon: 369
VOEST, E.E. see KUPPENS, I.E.L.M.
VON WOLFF, M. see FRÖHLICH, M.
VULTO, A.G. see VISSER, L.E.
WAKAUMI, M. see TSURUOKA, S.
WALTER-SACK, I. see FRÖHLICH, M.
WAN ADNAN, W.A. see GAN, S.H.
WANG, Y. see KOVARIK, J.M.
WARRINGTON, S. see BOYCE, M.
WARWICK, M.J. see SIMONSON, S.G.
WATKINS, C.L. see CANTARINI, M.V.
WATKINS, W. see MITHWANI, S.
WEBB, D.J. see ATTINÀ, T.
WEBB, D.J. see CARLSON, R.V.
WEBB, D.J. see CRUDEN, N.L.
WEBB, D.J. see LESLIE, S.J.
WEBB, D.J. see OLIVER, J.J.
WEBB. D.J. see PAYNE, R.A.
WEIL, A. see SOBUE, S.
WEIMAR, W. see HESSELINK, D.A.
WEISS, J. & HAEFELI, W.E. Genotyping of the A6986G polymorphism of CYP3A5: 663
WEISS, J. see FRÖHLICH, M.
WELLER, C. see BJARNASON, I.T.
WENK, M., TODESCO, L. & KRÄHENBÜHL, S. Effect of St John's Wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xanthine oxidase in healthy males and females: 495
WENZEL, R.R., MITCHELL, A., SIFFERT, W., BÜHRMANN, S., PHILIPP, T. & SCHÄFERS, R.F. The I1-imidazoline agonist moxonidine decreases sympathetic tone under physical and mental stress: 545
WEXLER, D. see COURTNEY, R.
WHITE, J.M. see FOSTER, D.J.R.
WHITTINGTON, D. see KHARASCH, E.D.
WILFFERT, B. see VAN ROON, E.N.
WILKINS, M.R. Experimental Therapeutics: 354
WILLIAMS, D. see REID, J.; SIMPSON, C.R.
WILLIAMS, D., BENNETT, K. & FEELY, J. Increased prescribing for osteoporosis following exposure to glucocorticoids particularly inhaled steroids: 669
WILLIAMS, I.L. see RAMBARAN, C.
WILLIAMS, K.M. see JIANG, X.
WILSON, A.M., THABANE, L. & HOLBROOK, A. Application of data mining techniques in pharmacovigilance: 127
WILSON, C. see PORTNER, R.
WILSON, J.H.P. see VISSER, L.E.
WILTING, I., MOOLENAAR, M., MOVIG, K.L.L., HEKSTER, Y.A., BROUWERS, J.R.B.J. & EGBERTS, A.C.G. Determinants of elevations of lithium serum levels into the toxic range: 369
WISE, S.D. see HUA, T.C.
WITHEROW, F.N. see CRUDEN, N.L.
WITTEMAN, J.C.M. see MAITLAND-VAN DER ZEE, A.H.
WITTEVEEN, E. see KUPPENS, I.E.L.M.
WOLBOLD, R. see COLLER, J.K.
WOLLBRATT M. see JOHNSTON, D.
WOOD, A.J.J. see DISHY, V.
WOOD, P. see KAMALI, F.
WOODHOUSE, K.W. see ROUTLEDGE, P.A.
WOOLDRIDGE, C.L. see PURKINS, L.
WORTHLEY, M.I., CORTI, R. & WORTHLEY, S.G. Vasopeptidase inhibitors: will they have a role in clinical practice?: 27
WORTHLEY, S.G. see WORTHLEY, M.I.
WU, Y. see NAISBITT, D.J.
WU, Y., FARRELL, J., PIRMOHAMED, M., PARK, B.K. & NAISBITT, D.J. Drug-specific proliferation of lymphocytes from patients hypersensitive to carbamazepine and oxcarbazepine: cross-reactivity and possible clinical implications: 683
WYNNE, H. see KAMALI, F.
YASUHARA, H. see FUKAZAWA, I.
YASUI-FURUKORI, N., MIHARA, K., TAKAHATA, T., SUZUKI, A., NAKAGAMI, T., DE VRIES, R., TATEISHI, T., KONDO, T. & KANEKO S. Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes: 569
YASUI-FURUKORI, N., TAKAHATA, T., NAKAGAMI, T., YOSHIYA, G., INOUE, Y., KANEKO, S. & TATEISHI, T. Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes: 487
YATES, R. see KÅGEDAL, M.
YEO, K.R. see PORTNER, R.
YEO, W.W. see BECK, C.R.
YEO, W.W. see PORTNER, R.
YOSHIYA, G. see YASUI-FURUKORI, N.
ZAHIR, H., MCCAUGHAN, G., GLEESON, M., NAND, R.A. & MCLACHLAN, A.J. Factors affecting variability in distribution of tacrolimus in liver transplant recipients: 298
ZANGER, U.M. see COLLER, J.K.
ZEITLINGER, M. see BELLMANN, R.
ZUIDEVELD, K.P. see SWART, E.L.
ZULMI, W. see GAN, S.H.